regorafenib

FDA gives Bayer’s colon cancer drug “priority”

  • Thu, 06/28/2012 - 2:29pm

The U.S. Food and Drug Administration accepted Bayer’s experimental drug regorafenib for priority review, which could make it marketable in a matter of six months.

Pages

Brought to you by Spangenberg Shibley & Liber, LLP © 2012